The Sydney-based medical device company announced that its non-renounceable entitlement offer had raised about $2 million and was fully subscribed, including the underwriting commitment from Bell Potter Securities.

Firebrick Pharma has appointed experienced pharmaceutical executive Nilesh Wadhwa to lead its global business development and licensing efforts as the company pushes to rapidly expand international approvals and sales of its Nasodine product range.

The Perth and San Francisco-based biotechnology company announced that discussions with the FDA confirmed key elements of the clinical trial required to support a future New Drug Application for the therapy.

Australian immuno-oncology company Imugene (ASX:IMU) has moved to accelerate development of its lead cancer therapy after reporting encouraging clinical results, while launching a capital raising to fund the next phase of trials.

Patrys (ASX:PAB) has taken significant steps toward advancing a potential new treatment for delirium into human clinical trials, including manufacturing and regulatory preparations for its experimental drug candidate RLS-2201.

Tetratherix (ASX:TTX) has taken a significant step forward in the development of its prostate cancer technology, advancing its Tutelix spacer toward an international pivotal trial following encouraging early clinical results and the successful completion of a Series A capital raise by its joint venture partner.

Mesoblast (ASX:MSB) has appointed physician scientist Dr Teresa Montagut to lead its clinical development and medical affairs efforts, strengthening the company’s leadership team as it expands its portfolio of cell therapies for inflammatory diseases.

Telix Pharmaceuticals (ASX:TLX) has reported positive early outcomes from the first part of its global Phase 3 ProstACT study, marking an important step in the development of a new targeted treatment for advanced prostate cancer.

The $1.5 billion project builds on more than $3 billion the global biopharmaceutical company has already invested in its United States operations since 2018 and is expected to create at least 300 new jobs alongside hundreds of construction roles.

Imugene (ASX:IMU) has reported encouraging early clinical results from its ongoing Phase 1b study of Azer Cel, an off-the-shelf CAR T cell therapy designed to treat several advanced blood cancers.

Nanosonics (ASX:NAN) has reached an important regulatory milestone after the United States Food and Drug Administration granted 510(k) clearance that broadens the range of endoscopes compatible with the company’s CORIS system.

Island Pharmaceuticals (ASX:ILA) has entered a strategic research collaboration with the Burnet Institute to expand the development potential of its antiviral drug portfolio and target a broader range of global viral threats.

New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide.

Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain.

Seven Australian medtech companies are being supported to accelerate their pathway into local procurement through a national capability program aimed at strengthening the adoption of homegrown medical technologies.

PYC Therapeutics (ASX:PYC) has completed the retail component of a major capital raising, adding approximately $47 million to its funding as the biotechnology company continues to advance its precision medicine programs for genetic diseases.

Firebrick Pharma (ASX:FRE) is preparing for a pivotal year in 2026 as it accelerates the commercial expansion of its Nasodine product portfolio and pushes into new international markets.